EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA, ESLAW) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ...
ARTEMIS can unlock the potential of adoptive T-cell therapies by targeting intracellular proteins that are presently not druggable by conventional approaches that target only cell surface proteins.” — ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback